MedDataX Logo

Randomized, Double-Blind, Placebo-Controlled, Forced-Titration, Comparing Telmisartan vs Valsartan. Taken Orally for Eight Weeks in Patients With Stage 1 and Stage 2 Hypertension

NCT ID: NCT00168779

Last Updated: 2017-12-28

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

1185 participants

Study Classification

INTERVENTIONAL

Study Start Date

2005-09-30

Study Completion Date

2006-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary objective of this study is to compare the effectiveness of telmisartan 80 mg / hydrochlorothiazide 25 mg \[Micardis HCT\] to valsartan 160 mg / hydrochlorothiazide 25 mg \[Diovan HCT\] and placebo in the treatment of Stage 1 and Stage 2 hypertension.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hypertension

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

telmisartan 80 mg / hydrochlorothiazide 25 mg

Intervention Type DRUG

valsartan 160 mg / hydrochlorothiazide 25 mg

Intervention Type DRUG

placebo

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Ability to provide written informed consent.
2. Age 18 years or older
3. Ability to stop current antihypertensive therapy without unacceptable risk to the patient (investigator's discretion)
4. Seated cuff DBP of ? 95 mmHg at Visit 2 (baseline)

Exclusion Criteria

1. Pre-menopausal women (last menstruation ? 1 year prior to start of run-in period) who:

1. are not surgically sterile and/or
2. are nursing or pregnant
3. are of child-bearing potential and are NOT practicing acceptable means of birth control, do NOT plan to continue using this method throughout the study and do NOT agree to submit to periodic pregnancy testing during participation in studies of \> 3-months duration. Acceptable methods of birth control include oral, implantable, transdermal, or injectable contraceptives, and Intra-Uterine Device (IUD).
2. Known or suspected secondary hypertension.
3. Mean seated SBP \>= 180 mmHg or mean seated DBP \>= 120 mmHg during any clinic visit prior to randomization.
4. Hepatic and/or renal dysfunction as defined by the following laboratory parameters:

1. SGPT (ALT) or SGOT (AST) \> 2 times the upper limit of normal range, or
2. Serum creatinine \> 3.0 mg/dL or creatinine clearance \< 0.6 ml/sec.
5. Bilateral renal artery stenosis, renal artery stenosis in a solitary kidney, post-renal transplant or with only one kidney.
6. Clinically relevant hypokalemia or hyperkalemia.
7. Uncorrected volume depletion.
8. Uncorrected sodium depletion.
9. Primary aldosteronism.
10. Hereditary fructose intolerance.
11. Biliary obstructive disorders, cholestatis or moderate to severe hepatic in sufficiency.
12. Patients who have previously experienced symptoms characteristic of angioedema during treatment with ACE inhibitors or angiotensin II receptor antagonists.
13. History of drug or alcohol dependency within six months prior to start of run-in period.
14. Chronic administration of any medications known to affect blood pressure, exc
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Boehringer Ingelheim

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Boehringer Ingelheim

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Boehringer Ingelheim

Role: STUDY_CHAIR

Boehringer Ingelheim

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

502.476.074 Boehringer Ingelheim Investigational Site

Athens, Alabama, United States

Site Status

502.476.059 Boehringer Ingelheim Investigational Site

Birmingham, Alabama, United States

Site Status

502.476.071 Boehringer Ingelheim Investigational Site

Birmingham, Alabama, United States

Site Status

502.476.079 Boehringer Ingelheim Investigational Site

Birmingham, Alabama, United States

Site Status

502.476.014 Boehringer Ingelheim Investigational Site

Huntsville, Alabama, United States

Site Status

502.476.031 Boehringer Ingelheim Investigational Site

Huntsville, Alabama, United States

Site Status

502.476.110 Boehringer Ingelheim Investigational Site

Huntsville, Alabama, United States

Site Status

502.476.037 Boehringer Ingelheim Investigational Site

Mobile, Alabama, United States

Site Status

502.476.061 Boehringer Ingelheim Investigational Site

Glendale, Arizona, United States

Site Status

502.476.066 Boehringer Ingelheim Investigational Site

Carlisle, Arkansas, United States

Site Status

502.476.067 Boehringer Ingelheim Investigational Site

Buena Park, California, United States

Site Status

502.476.086 Boehringer Ingelheim Investigational Site

Encinitas, California, United States

Site Status

502.476.124 Boehringer Ingelheim Investigational Site

Greenbrae, California, United States

Site Status

502.476.005 Boehringer Ingelheim Investigational Site

Long Beach, California, United States

Site Status

502.476.024 Boehringer Ingelheim Investigational Site

Los Angeles, California, United States

Site Status

502.476.029 Boehringer Ingelheim Investigational Site

Redondo Beach, California, United States

Site Status

502.476.048 Boehringer Ingelheim Investigational Site

Riverside, California, United States

Site Status

502.476.073 Boehringer Ingelheim Investigational Site

Sacramento, California, United States

Site Status

502.476.087 Boehringer Ingelheim Investigational Site

San Diego, California, United States

Site Status

502.476.111 Boehringer Ingelheim Investigational Site

San Francisco, California, United States

Site Status

502.476.050 Boehringer Ingelheim Investigational Site

Santa Ana, California, United States

Site Status

502.476.026 Boehringer Ingelheim Investigational Site

Spring Valley, California, United States

Site Status

502.476.033 Boehringer Ingelheim Investigational Site

Tulsa, California, United States

Site Status

502.476.019 Boehringer Ingelheim Investigational Site

Boulder, Colorado, United States

Site Status

502.476.101 Boehringer Ingelheim Investigational Site

Highlands Ranch, Colorado, United States

Site Status

502.476.053 Boehringer Ingelheim Investigational Site

Farmington, Connecticut, United States

Site Status

502.476.032 Boehringer Ingelheim Investigational Site

Newark, Delaware, United States

Site Status

502.476.041 Boehringer Ingelheim Investigational Site

Coral Gables, Florida, United States

Site Status

502.476.108 Boehringer Ingelheim Investigational Site

DeLand, Florida, United States

Site Status

502.476.015 Boehringer Ingelheim Investigational Site

Fort Lauderdale, Florida, United States

Site Status

502.476.044 Boehringer Ingelheim Investigational Site

Hollywood, Florida, United States

Site Status

502.476.058 FPA Clinical Research

Kissimmee, Florida, United States

Site Status

502.476.052 Boehringer Ingelheim Investigational Site

Largo, Florida, United States

Site Status

502.476.080 Boehringer Ingelheim Investigational Site

Melbourne, Florida, United States

Site Status

502.476.021 Boehringer Ingelheim Investigational Site

Panama City, Florida, United States

Site Status

502.476.012 Boehringer Ingelheim Investigational Site

Pembroke Pines, Florida, United States

Site Status

502.476.036 Boehringer Ingelheim Investigational Site

Pembroke Pines, Florida, United States

Site Status

502.476.065 Boehringer Ingelheim Investigational Site

Pembroke Pines, Florida, United States

Site Status

502.476.022 Boehringer Ingelheim Investigational Site

Atlanta, Georgia, United States

Site Status

502.476.049 Boehringer Ingelheim Investigational Site

Atlanta, Georgia, United States

Site Status

502.476.008 Boehringer Ingelheim Investigational Site

Conyers, Georgia, United States

Site Status

502.476.075 Boehringer Ingelheim Investigational Site

Decatur, Georgia, United States

Site Status

502.476.018 Boehringer Ingelheim Investigational Site

Chicago, Illinois, United States

Site Status

502.476.047 Boehringer Ingelheim Investigational Site

Chicago, Illinois, United States

Site Status

502.476.004 Boehringer Ingelheim Investigational Site

Peoria, Illinois, United States

Site Status

502.476.062 Boehringer Ingelheim Investigational Site

Evansville, Indiana, United States

Site Status

502.476.063 Boehringer Ingelheim Investigational Site

Evansville, Indiana, United States

Site Status

502.476.051 Boehringer Ingelheim Investigational Site

Indianapolis, Indiana, United States

Site Status

502.476.084 Boehringer Ingelheim Investigational Site

South Bend, Indiana, United States

Site Status

502.476.090 Boehringer Ingelheim Investigational Site

South Bend, Indiana, United States

Site Status

502.476.100 Boehringer Ingelheim Investigational Site

Newton, Kansas, United States

Site Status

502.476.003 Boehringer Ingelheim Investigational Site

Wichita, Kansas, United States

Site Status

502.476.038 Boehringer Ingelheim Investigational Site

Wichita, Kansas, United States

Site Status

502.476.002 Boehringer Ingelheim Investigational Site

Louisville, Kentucky, United States

Site Status

502.476.116 Boehringer Ingelheim Investigational Site

New Orleans, Louisiana, United States

Site Status

502.476.035 Boehringer Ingelheim Investigational Site

Oxon Hill, Maryland, United States

Site Status

502.476.010 Boehringer Ingelheim Investigational Site

Troy, Michigan, United States

Site Status

502.476.028 Boehringer Ingelheim Investigational Site

Brooklyn Center, Minnesota, United States

Site Status

502.476.057 Boehringer Ingelheim Investigational Site

Edina, Minnesota, United States

Site Status

502.476.055 Boehringer Ingelheim Investigational Site

Kansas City, Missouri, United States

Site Status

502.476.114 Boehringer Ingelheim Investigational Site

St Louis, Missouri, United States

Site Status

502.476.112 Boehringer Ingelheim Investigational Site

Omaha, Nebraska, United States

Site Status

502.476.126 Boehringer Ingelheim Investigational Site

Omaha, Nebraska, United States

Site Status

502.476.125 Boehringer Ingelheim Investigational Site

Las Vegas, Nevada, United States

Site Status

502.476.120 Boehringer Ingelheim Investigational Site

Berlin, New Jersey, United States

Site Status

502.476.088 Boehringer Ingelheim Investigational Site

Ship Bottom, New Jersey, United States

Site Status

502.476.089 Boehringer Ingelheim Investigational Site

Turnersville, New Jersey, United States

Site Status

502.476.068 Boehringer Ingelheim Investigational Site

Brooklyn, New York, United States

Site Status

502.476.122 Boehringer Ingelheim Investigational Site

Hamburg, New York, United States

Site Status

502.476.020 Boehringer Ingelheim Investigational Site

Northport, New York, United States

Site Status

502.476.025 Boehringer Ingelheim Investigational Site

Rochester, New York, United States

Site Status

502.476.091 Boehringer Ingelheim Investigational Site

Williamsville, New York, United States

Site Status

502.476.046 Boehringer Ingelheim Investigational Site

Burlington, North Carolina, United States

Site Status

502.476.083 Boehringer Ingelheim Investigational Site

Charlotte, North Carolina, United States

Site Status

502.476.042 Boehringer Ingelheim Investigational Site

Raleigh, North Carolina, United States

Site Status

502.476.095 Boehringer Ingelheim Investigational Site

Salisbury, North Carolina, United States

Site Status

502.476.027 Boehringer Ingelheim Investigational Site

Winston-Salem, North Carolina, United States

Site Status

502.476.034 Boehringer Ingelheim Investigational Site

Cincinnati, Ohio, United States

Site Status

502.476.060 Boehringer Ingelheim Investigational Site

Cincinnati, Ohio, United States

Site Status

502.476.016 Boehringer Ingelheim Investigational Site

Columbus, Ohio, United States

Site Status

502.476.023 Boehringer Ingelheim Investigational Site

Columbus, Ohio, United States

Site Status

502.476.128 Boehringer Ingelheim Investigational Site

Columbus, Ohio, United States

Site Status

502.476.064 Boehringer Ingelheim Investigational Site

Kettering, Ohio, United States

Site Status

502.476.103 Boehringer Ingelheim Investigational Site

Olmsted Falls, Ohio, United States

Site Status

502.476.007 Boehringer Ingelheim Investigational Site

Oklahoma City, Oklahoma, United States

Site Status

502.476.113 Boehringer Ingelheim Investigational Site

Oklahoma City, Oklahoma, United States

Site Status

502.476.030 Boehringer Ingelheim Investigational Site

Tulsa, Oklahoma, United States

Site Status

502.476.104 Boehringer Ingelheim Investigational Site

Portland, Oregon, United States

Site Status

502.476.109 Boehringer Ingelheim Investigational Site

Erie, Pennsylvania, United States

Site Status

502.476.094 Boehringer Ingelheim Investigational Site

Harleysville, Pennsylvania, United States

Site Status

502.476.121 Boehringer Ingelheim Investigational Site

Penndel, Pennsylvania, United States

Site Status

502.476.072 Boehringer Ingelheim Investigational Site

Philadelphia, Pennsylvania, United States

Site Status

502.476.076 Boehringer Ingelheim Investigational Site

Springfield, Pennsylvania, United States

Site Status

502.476.013 Boehringer Ingelheim Investigational Site

East Providence, Rhode Island, United States

Site Status

502.476.085 Boehringer Ingelheim Investigational Site

Cordova, Tennessee, United States

Site Status

502.476.096 Boehringer Ingelheim Investigational Site

Jackson, Tennessee, United States

Site Status

502.476.081 Boehringer Ingelheim Investigational Site

New Tazewell, Tennessee, United States

Site Status

502.476.082 Boehringer Ingelheim Investigational Site

Selmer, Tennessee, United States

Site Status

502.476.039 Boehringer Ingelheim Investigational Site

Carrollton, Texas, United States

Site Status

502.476.056 Boehringer Ingelheim Investigational Site

Dallas, Texas, United States

Site Status

502.476.069 Boehringer Ingelheim Investigational Site

Dallas, Texas, United States

Site Status

502.476.107 Boehringer Ingelheim Investigational Site

Dallas, Texas, United States

Site Status

502.476.070 Boehringer Ingelheim Investigational Site

Killeen, Texas, United States

Site Status

502.476.001 Boehringer Ingelheim Investigational Site

Bountiful, Utah, United States

Site Status

502.476.006 Boehringer Ingelheim Investigational Site

Salt Lake City, Utah, United States

Site Status

502.476.017 Boehringer Ingelheim Investigational Site

Salt Lake City, Utah, United States

Site Status

502.476.097 Boehringer Ingelheim Investigational Site

Sandy City, Utah, United States

Site Status

502.476.098 Boehringer Ingelheim Investigational Site

Sandy City, Utah, United States

Site Status

502.476.011 Boehringer Ingelheim Investigational Site

Falls Church, Virginia, United States

Site Status

502.476.093 Boehringer Ingelheim Investigational Site

Norfolk, Virginia, United States

Site Status

502.476.078 Boehringer Ingelheim Investigational Site

Tacoma, Washington, United States

Site Status

502.476.106 Boehringer Ingelheim Investigational Site

Menomonee Falls, Wisconsin, United States

Site Status

502.476.105 Boehringer Ingelheim Investigational Site

Milwaukee, Wisconsin, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Related Links

Access external resources that provide additional context or updates about the study.

https://www.ncbi.nlm.nih.gov/pubmed/22844584

Related Info

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

502.476

Identifier Type: -

Identifier Source: org_study_id